Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)
Open Access
- 14 May 2020
- journal article
- review article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 146 (7), 1829-1845
- https://doi.org/10.1007/s00432-020-03236-4
Abstract
Purpose The outcome of RCC has improved considerably in the last few years, and the treatment options have increased. LACOG-GU and LARCG held a consensus meeting to develop guidelines to support the clinical decisions of physicians and other health professionals involved in the care of RCC patients. Methods Eighty questions addressing relevant advanced RCC treatments were previously formulated by a panel of experts. The voting panel comprised 26 specialists from the LACOG-GU/LARCG. Consensus was determined as 75% agreement. For questions with less than 75% agreement, a new discussion was held, and consensus was determined by the majority of votes after the second voting session. Results The recommendations were based on the highest level of scientific evidence or by the opinion of the RCC experts when no relevant research data were available. Conclusion This manuscript provides guidance for advanced RCC treatment according to the LACOG-GU/LARCG expert recommendations.Keywords
Funding Information
- Roche
- Novartis
- Pfizer
- Bristol-Myers Squibb
This publication has 97 references indexed in Scilit:
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2013
- Renal Medullary Carcinoma Response to Chemotherapy: a Referral Center Experience in BrazilRare Tumors, 2013
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinomaPediatric Blood & Cancer, 2010
- Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell CarcinomaJournal of Urology, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Palliative CareJournal of Pain and Symptom Management, 2002
- Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institutionEuropean Journal Of Cancer, 1996